Bionaut Pharmaceuticals (Cambridge, MA, USA) has named Kees Been CEO. He joins Bionaut from Biogen, where he served most recently as senior vice president of the company's oncology business unit.

Vela Pharmaceuticals (Lawrenceville, NJ, USA) has announced the promotions of Jeff Calcagno to chief business officer and Steven M. Leventer to senior vice president, research and development. Dr. Calcagno joined the company in July 2002 as CFO and vice president, finance. Dr. Leventer was promoted from vice president, clinical R&D.

Joseph M. Davie has been elected to the board of directors of Curis (Cambridge, MA, USA). Dr. Davie was most recently senior vice president of research at Biogen, and he also held several senior positions at G.D. Searle and Co., including senior vice president of science and technology and president of R&D.

Adolf Haellmayr has been named to the supervisory board at Munich Biotech (Neuried/Munich, Germany). Mr. Haellmayr was most recently director of corporate accounting at Allianz Aktiengesellschaft.

George V. Hager, Jr. has been named to the board of directors at Adolor (Exton, PA, USA). Mr. Hager, who is CEO of Genesis HealthCare Corp., will also serve as a member of the audit committee of Adolor's board.

Lexicon Genetics (The Woodlands, TX, USA) has named William E. Heydorn vice president of preclinical development. Dr. Heydorn joins Lexicon from Forest Laboratories, where he served as director, medical affairs, and director, scientific communications.

Microbia (Cambridge, MA, USA) has appointed Michael J. Higgins to the position of chief financial officer and senior vice president of finance and strategic planning. Previously, he served as vice president, corporate finance at Genzyme and vice president, business development at Genzyme Tissue Repair, one of its subsidiaries.

Millennium Pharmaceuticals (Cambridge, MA, USA) has announced that vice chairperson Vaughn Kailian has relinquished his daily responsibilities for commercial operations and plans to leave the company in December 2003, following the transition of his duties to his successor. Mr. Kailian will retain his position as vice chairperson and continue to serve as a member of the board of directors. Millennium CFO Kenneth Bate has been appointed to the additional position of executive vice president, head of commercial operations. The company has also announced that Marsha Fanucci has been appointed to the newly created position of vice president of finance and corporate strategy. She has served as vice president, mergers and acquisitions since joining Millennium in July 2000.

Medicure (Winnipeg, MB, Canada) has appointed Ahmad Khalil as director, scientific affairs and medical officer for the company's clinical studies. Dr. Khalil has been a researcher and lecturer at the Montreal Heart Institute, and has been a practicing surgeon in Europe.

Skip Klein has been named to Genaissance Pharmaceuticals' (New Haven, CT, USA) board of directors. He is the founder and managing director of Gauss Capital Advisors, and has 15 years of healthcare investment experience at T. Rowe Price Associates, The Kaufmann Fund and MPM Capital. Mr. Klein also serves on the boards of Guilford Pharmaceuticals and NPS Pharmaceuticals, where he is chairman of the audit committee.

Langdon Miller has joined PTC Therapeutics (S. Plainfield, NJ, USA) as chief medical officer. He joins the company from Pharmacia, where he was most recently vice president of global clinical research in oncology.

Affymax (Palo Alto, CA, USA) has announced the appointment of Arlene M. Morris as president and CEO. Ms. Morris was most recently president and CEO of the consulting firm Clearview Projects, and has served in senior business development positions at Scios, Coulter and Corixa.

IntegraGen (Paris, France) has announced the appointment of Jan Mous, formerly chief scientific officer and member of the executive board of LION Bioscience, as its new CEO and chairman of the board of directors. Dr. Mous also served as global head of genomics technology for Roche, and managing director of its genetics and genomics technology platform.

Martin A. Wasserman has been promoted to the position of senior vice president of discovery research at AtheroGenics (Atlanta, GA, USA). Dr. Wasserman also serves as the company's chief scientific officer.